Deep learning-based quantification of CT changes after 1 year of pirfenidone treatment as a prognostic marker in idiopathic pulmonary fibrosis. [PDF]
Lee JY +7 more
europepmc +1 more source
Cardiovascular complications in idiopathic pulmonary fibrosis and the emerging concept of the heart-lung fibrotic axis: a narrative review. [PDF]
Graczyk P +2 more
europepmc +1 more source
Quality of life instruments in idiopathic pulmonary fibrosis: a COSMIN-based systematic review. [PDF]
Zhang E +5 more
europepmc +1 more source
Smoking-Related Clinical and Molecular Abnormalities in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension. [PDF]
Zhyvylo I +7 more
europepmc +1 more source
Smoking exposures and mortality risk in individuals with idiopathic pulmonary fibrosis: a UK Biobank cohort study. [PDF]
Tu Q +14 more
europepmc +1 more source
Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis. [PDF]
Ayyadurai VAS, Manoharan Y, Deonikar P.
europepmc +1 more source
Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study. [PDF]
Yanalak A, Yazıcı O.
europepmc +1 more source
Translation, Cultural Adaptation, and Validation of the Turkish Version of the St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis (SGRQ-I). [PDF]
Pehlivan E +9 more
europepmc +1 more source
Clinical and prognostic characteristics of concurrent small cell lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective study. [PDF]
Shi Y +8 more
europepmc +1 more source
Genes, gut microbiome and lungs: untangling the web of idiopathic pulmonary fibrosis. [PDF]
Hernandez-Beeftink T +5 more
europepmc +1 more source

